AbbVie Inc. (NYSE:ABBV) Shares Acquired by Fishman Jay A Ltd. MI

Fishman Jay A Ltd. MI increased its holdings in AbbVie Inc. (NYSE:ABBV) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 68,907 shares of the company’s stock after acquiring an additional 954 shares during the quarter. AbbVie makes up 1.1% of Fishman Jay A Ltd. MI’s portfolio, making the stock its 19th biggest position. Fishman Jay A Ltd. MI’s holdings in AbbVie were worth $12,245,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ABBV. AMF Tjanstepension AB acquired a new position in shares of AbbVie in the third quarter worth about $8,777,000. Redhawk Wealth Advisors Inc. raised its stake in AbbVie by 3.1% during the third quarter. Redhawk Wealth Advisors Inc. now owns 2,609 shares of the company’s stock valued at $515,000 after buying an additional 78 shares in the last quarter. Grove Bank & Trust raised its stake in AbbVie by 1.2% during the third quarter. Grove Bank & Trust now owns 12,859 shares of the company’s stock valued at $2,539,000 after buying an additional 149 shares in the last quarter. Sivia Capital Partners LLC raised its stake in AbbVie by 2.2% during the third quarter. Sivia Capital Partners LLC now owns 4,493 shares of the company’s stock valued at $887,000 after buying an additional 98 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in AbbVie during the third quarter valued at approximately $46,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of several research reports. Wolfe Research initiated coverage on AbbVie in a research note on Friday, November 15th. They set an “outperform” rating and a $205.00 price objective on the stock. Morgan Stanley upped their price objective on AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Leerink Partnrs upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Wells Fargo & Company upped their price objective on AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. cut their price objective on AbbVie from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $208.35.

AbbVie Stock Up 0.8 %

ABBV opened at $191.81 on Wednesday. AbbVie Inc. has a 12 month low of $153.58 and a 12 month high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The stock has a market cap of $338.96 billion, a P/E ratio of 79.92, a P/E/G ratio of 1.53 and a beta of 0.58. The stock’s 50 day moving average price is $177.71 and its 200 day moving average price is $185.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same period last year, the firm earned $2.79 earnings per share. As a group, research analysts predict that AbbVie Inc. will post 12.32 earnings per share for the current year.

Insider Activity

In other news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.25% of the stock is owned by insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.